Johnson & Johnson
267.08USD
-2.0400 (-0.76%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $2.43▼ | $3.02 | 0 | 4 |
| Next quarter | $3.03▲ | $2.98 | 1 | 3 |
| Current year | $11.05▼ | $11.57 | 0 | 4 |
| Next year | $12.31▼ | $12.72 | 2 | 2 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $2.85 | $2.9 | +0.05 (+1.6%) |
| 2026-03-31 | $2.68 | $2.7 | +0.02 (+0.8%) |
| 2025-12-31 | $2.46 | $2.46 | -0.00 (-0.1%) |
| 2025-09-30 | $2.76 | $2.8 | +0.04 (+1.5%) |
380 ratings from 36 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| UBS | Maintained | Buy | $280 $320 | Sep 2, 2026 |
| Guggenheim | Maintained | Buy | $270 $287 | Aug 6, 2026 |
| Wells Fargo | Maintained | Overweight | $272 $282 | Aug 3, 2026 |
| Guggenheim | Reiterated | Buy | $270 | Jul 17, 2026 |
| Raymond James | Maintained | Outperform | $258 $265 | Jul 16, 2026 |
| RBC Capital | Reiterated | Outperform | $287 | Jul 16, 2026 |
| Wells Fargo | Maintained | Overweight | $263 $272 | Jul 16, 2026 |
| Morgan Stanley | Maintained | Overweight | $284 $294 | Jul 16, 2026 |
| TD Cowen | Maintained | Buy | $250 $300 | Jul 13, 2026 |
| RBC Capital | Maintained | Outperform | $265 $287 | Jul 13, 2026 |
| B of A Securities | Maintained | Neutral | $254 $263 | Jul 10, 2026 |
| Morgan Stanley | Maintained | Overweight | $283 $284 | Jul 8, 2026 |
| Citigroup | Maintained | Buy | $285 $298 | Jul 8, 2026 |
| Guggenheim | Maintained | Buy | $266 $270 | Jun 26, 2026 |
| Leerink Partners | Upgraded from Market Perform | Outperform | $265 | May 13, 2026 |
| Barclays | Maintained | Equal-Weight | $234 $255 | Apr 15, 2026 |
| Stifel | Maintained | Hold | $220 $250 | Apr 15, 2026 |
| Wells Fargo | Maintained | Overweight | $240 $263 | Apr 15, 2026 |
| Morgan Stanley | Maintained | Overweight | $262 $267 | Apr 10, 2026 |
| RBC Capital | Reiterated | Outperform | $255 | Mar 30, 2026 |
| Barclays | Maintained | Equal-Weight | $217 $234 | Mar 19, 2026 |
| HSBC | Maintained | Buy | $265 $280 | Mar 17, 2026 |
| Citigroup | Maintained | Buy | $250 $274 | Mar 11, 2026 |
| JP Morgan | Maintained | Neutral | $225 $250 | Mar 5, 2026 |
| RBC Capital | Maintained | Outperform | $240 $255 | Feb 3, 2026 |
79 filings from 14 insiders · 7 buy / 7 sell over 6m
Officers and directors of JNJ, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Schmid TimothyOfficer, EVP, WW Chair, MedTech | ExerciseEmployee Stock Options (Right to Buy) | 22.5k | — | — | Sep 2, 2026 |
| Schmid TimothyOfficer, EVP, WW Chair, MedTech | ExerciseEmployee Stock Options (Right to Buy) | 11.1k | — | — | Sep 2, 2026 |
| Schmid TimothyOfficer, EVP, WW Chair, MedTech | Sell | 22.5k | $274.74 | $6.19M | Sep 2, 2026 |
| Schmid TimothyOfficer, EVP, WW Chair, MedTech | Exercise | 22.5k | $151.41 | $3.41M | Sep 2, 2026 |
| Schmid TimothyOfficer, EVP, WW Chair, MedTech | Sell | 11.1k | $274.74 | $3.04M | Sep 2, 2026 |
| Schmid TimothyOfficer, EVP, WW Chair, MedTech | Exercise | 11.1k | $131.94 | $1.46M | Sep 2, 2026 |
| TAUBERT JENNIFER LOfficer | Exercise | 15.0k | $115.67 | $1.74M | Aug 17, 2026 |
| TAUBERT JENNIFER LOfficer | Sell | 15.0k | $263.36 | $3.95M | Aug 17, 2026 |
| DUATO JOAQUIN BOIXChief Executive Officer | Exercise | 123.3k | $115.67 | $14.26M | Aug 13, 2026 |
| DUATO JOAQUIN BOIXChief Executive Officer | Sell | 123.3k | $261.00 | $32.20M | Aug 13, 2026 |
| FORMINARD ELIZABETHOfficer | Exercise | 9.3k | $131.94 | $1.23M | Aug 6, 2026 |
| FORMINARD ELIZABETHOfficer | Sell | 15.9k | $255.93 | $4.09M | Aug 6, 2026 |
| DUATO JOAQUIN BOIXChief Executive Officer | Sell | 48.5k | $258.06 | $12.52M | Aug 5, 2026 |
| BROADHURST VANESSAOfficer | Exercise | 23.1k | $129.51 | $3.01M | Jul 20, 2026 |
| BROADHURST VANESSAOfficer | Sell | 23.1k | $251.27 | $5.79M | Jul 20, 2026 |
| WENGEL KATHRYN EChief Technology Officer | Exercise | 10.0k | $115.67 | $1.16M | Jun 11, 2026 |
| WENGEL KATHRYN EChief Technology Officer | Sell | 10.0k | $241.15 | $2.41M | Jun 11, 2026 |
| REED JOHN COfficer | Other | 25.3k | — | — | May 1, 2026 |
| DECKER ROBERT JOfficer | Exercise | 4.1k | $115.67 | $471k | Feb 27, 2026 |
| DECKER ROBERT JOfficer | Sell | 4.1k | $247.87 | $1.01M | Feb 27, 2026 |
No analyst notes on JNJ yet.
Analyst Ratings
22 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 5 | 11 | 6 | 1 | 0 | Buy2.13 |
| 1 mo ago | 5 | 11 | 6 | 1 | 0 | Buy2.13 |
| 2 mo ago | 5 | 11 | 6 | 1 | 0 | Buy2.13 |
| 3 mo ago | 5 | 10 | 7 | 1 | 0 | Buy2.17 |